ABUS 8-K: SEC filing

Arbutus Biopharma Corporation

Filed with the SEC on Nov 10, 2026 · accession 0001171843-26-007311

ABUS filed a 8-K (current report) with the SEC on Nov 10, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Arbutus Biopharma Corporation issued a press release announcing its financial results for the third quarter ended September 30, 2026, furnished as Exhibit 99.1 to this Form 8-K.

For details, click here →How to read a 8-K →

Key details

RegistrantArbutus Biopharma Corporation

Chief financial officerTuan Nguyen

✦ Ask GOAX AI about this filing — what it means for ABUS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ABUS?

Click here

Frequently asked questions

What did ABUS file with the SEC on Nov 10, 2026?

ABUS filed a 8-K (SEC filing). Arbutus Biopharma Corporation issued a press release announcing its financial results for the third quarter ended September 30, 2026, furnished as Exhibit 99.1 to this Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other ABUS SEC filings

Get alerts when ABUS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

ABUS overview ABUS analysis ABUS news Latest SEC filings